EPS for Aetna Inc. (AET) Expected At $1.18; 1 Analysts Are Bullish Foundation Medicine, Inc. (FMI) Last Week

January 22, 2018 - By Maria Brooks

Analysts expect Aetna Inc. (NYSE:AET) to report $1.18 EPS on January, 30.They anticipate $0.45 EPS change or 27.61% from last quarter’s $1.63 EPS. AET’s profit would be $384.88 million giving it 39.79 P/E if the $1.18 EPS is correct. After having $2.45 EPS previously, Aetna Inc.’s analysts see -51.84% EPS growth. The stock increased 1.25% or $2.31 during the last trading session, reaching $187.8. About 3.42 million shares traded. Aetna Inc. (NYSE:AET) has risen 28.84% since January 22, 2017 and is uptrending. It has outperformed by 12.14% the S&P500.

Among 9 analysts covering Foundation Medicine (NASDAQ:FMI), 1 have Buy rating, 0 Sell and 8 Hold. Therefore 11% are positive. Foundation Medicine had 12 analyst reports since July 30, 2015 according to SRatingsIntel. On Wednesday, November 4 the stock rating was downgraded by BTIG Research to “Neutral”. The firm earned “Neutral” rating on Tuesday, March 7 by Janney Capital. The firm has “Market Perform” rating given on Thursday, July 30 by JMP Securities. Benchmark downgraded Foundation Medicine, Inc. (NASDAQ:FMI) on Thursday, November 3 to “Hold” rating. On Monday, May 15 the stock rating was upgraded by BTIG Research to “Buy”. The firm earned “Neutral” rating on Wednesday, September 21 by UBS. The company was initiated on Monday, September 14 by BTIG Research. The company was downgraded on Wednesday, September 16 by Wells Fargo. See Foundation Medicine, Inc. (NASDAQ:FMI) latest ratings:

Investors sentiment decreased to 1.28 in 2017 Q3. Its down 0.51, from 1.79 in 2017Q2. It dropped, as 11 investors sold Foundation Medicine, Inc. shares while 18 reduced holdings. 7 funds opened positions while 30 raised stakes. 9.71 million shares or 0.07% less from 9.72 million shares in 2017Q2 were reported. The Maryland-based Proshare Advsrs Ltd has invested 0.01% in Foundation Medicine, Inc. (NASDAQ:FMI). Intll Grp holds 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI) for 9,606 shares. Strs Ohio invested in 0% or 18,700 shares. 672,835 are owned by Alliancebernstein Lp. Pnc Financial Services Group Inc holds 0% or 34 shares. Ipswich Investment Company has invested 0.26% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI). Bamco New York stated it has 0.02% in Foundation Medicine, Inc. (NASDAQ:FMI). Amp Cap Investors Ltd holds 5,550 shares or 0% of its portfolio. Old Natl Financial Bank In invested in 10,000 shares. Hanseatic Management Services has 0% invested in Foundation Medicine, Inc. (NASDAQ:FMI). Baillie Gifford & invested in 255,790 shares. New York-based Gilder Gagnon Howe And Limited has invested 0.86% in Foundation Medicine, Inc. (NASDAQ:FMI). Northern invested in 0% or 189,370 shares. Wells Fargo & Mn stated it has 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI). Fmr Ltd Limited Liability Company reported 81,328 shares.

The stock increased 1.36% or $0.9 during the last trading session, reaching $67.25. About 153,883 shares traded. Foundation Medicine, Inc. (NASDAQ:FMI) has risen 124.70% since January 22, 2017 and is uptrending. It has outperformed by 108.00% the S&P500.

Foundation Medicine, Inc. provides various molecular information products in the United States. The company has market cap of $2.46 billion. The companyÂ’s molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic information about each patientÂ’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. It currently has negative earnings. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer.

Aetna Inc. operates as a health care benefits firm in the United States. The company has market cap of $61.26 billion. It operates through three divisions: Health Care, Group Insurance, and Large Case Pensions. It has a 35.67 P/E ratio. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis.

Among 24 analysts covering Aetna (NYSE:AET), 10 have Buy rating, 0 Sell and 14 Hold. Therefore 42% are positive. Aetna has $205.0 highest and $12 lowest target. $170.80’s average target is -9.05% below currents $187.8 stock price. Aetna had 65 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was upgraded by Raymond James on Friday, November 3 to “Outperform”. As per Monday, November 14, the company rating was downgraded by Bernstein. Cowen & Co maintained the stock with “Buy” rating in Monday, October 23 report. On Tuesday, August 4 the stock rating was maintained by Sterne Agee CRT with “Buy”. Credit Suisse initiated the shares of AET in report on Wednesday, December 16 with “Neutral” rating. The stock has “Buy” rating by RBC Capital Markets on Monday, October 9. The rating was initiated by Credit Suisse on Friday, November 3 with “Hold”. Citigroup maintained it with “Buy” rating and $197 target in Thursday, November 2 report. The stock has “Outperform” rating by Credit Suisse on Friday, November 11. Evercore initiated it with “Buy” rating and $128 target in Friday, September 23 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: